Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pulmonary toxicity from novel antineoplastic agents.

I Dimopoulou1, A Bamias, P Lyberopoulos

  • 1Second Department of Critical Care Medicine, Attikon University Hospital, Athens, Greece. idimo@otenet.gr

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|November 18, 2005
PubMed
Summary

Most novel antineoplastic drugs can cause lung toxicity, primarily affecting lung tissue and sometimes leading to impaired function. Early detection and awareness are crucial for managing these serious side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the combination of atezolizumab with sacituzumab govitecan in patients with locally advanced or metastatic urothelial carcinoma and previously treated with a platinum-based treatment regimen (MORPHEUS-Urothelial Carcinoma).

ESMO open·2026
Same author

Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Healthcare resource utilization and associated costs in patients with metastatic castration-resistant prostate cancer in Greece.

Expert review of pharmacoeconomics & outcomes research·2025
Same author

European Myeloma Network Group review and consensus statement on primary plasma cell leukemia.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Real-World Treatment Patterns in Patients With Metastatic Castration-Resistant Prostate Cancer in Greece: The PROSPECT Study.

Clinical genitourinary cancer·2024
Same author

The complement cascade in lung injury and disease.

Respiratory research·2024

Area of Science:

  • Oncology
  • Pulmonology
  • Pharmacology

Background:

  • Pulmonary side-effects of novel antineoplastic agents are not well understood.
  • Characterizing these effects is essential for patient safety.

Purpose of the Study:

  • To comprehensively review and characterize the pulmonary toxicity associated with novel antineoplastic agents.
  • To inform clinicians about potential respiratory risks.

Main Methods:

  • Systematic literature search of Medline and other databases for studies on novel antineoplastic agents and lung toxicity.
  • Inclusion of English and non-English studies, conference abstracts, and data from Pneumotox and pharmaceutical websites.
  • Utilized keywords including drug names and terms like pulmonary toxicity, dyspnea, pneumonitis, and acute lung injury.

Related Experiment Videos

Main Results:

  • Most novel antineoplastic drugs can induce pulmonary toxicity, predominantly affecting the lung parenchyma.
  • Common manifestations include dyspnea and infiltrative lung disease (ILD), which can impair pulmonary function tests.
  • While ILD is often benign and treatable, fatalities have been reported, and the exact incidence of lung toxicity remains unclear.

Conclusions:

  • Clinicians must be aware of the significant potential for lung toxicity with most novel antineoplastic agents.
  • A high index of suspicion is warranted, especially when these agents are used concurrently with other cytotoxic drugs or radiation therapy.